Halaven Solution For Injection 0.5Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Halaven: Solution for injection (0.5mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

ERIBULIN is a chemotherapy drug. It is used to treat breast cancer.

In-Depth Information

Halaven 1mg/2ml Solution for Injection

NDC: 628560389
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Breast Cancer, Soft-tissue Sarcoma

Storage Information
Store in carton
Discard unused portion. Do not store for later use.
Do not freeze
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Halaven 1mg/2ml Solution for Injection

Reported Side Effects for Halaven 1mg/2ml Solution for Injection

Low Potassium Levels Incidence:
<5.4%*
Severity: SEVERE
Onset: DELAYED
Low Phosphate Level Incidence:
<3.2%*
Severity: SEVERE
Onset: DELAYED
Muscle Pain Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Mouth Ulcers Incidence:
<0.9%*
Severity: SEVERE
Onset: DELAYED
Stomach Pain Incidence:
<1.8%*
Severity: SEVERE
Onset: EARLY
Vomiting Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Weakness Incidence:
<10.0%*
Severity: SEVERE
Onset: DELAYED
Back Pain Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Paresthesias Incidence:
<8.0%*
Severity: SEVERE
Onset: DELAYED
Upset Stomach Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Joint Pain Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Bone Pain Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Tired Incidence:
<10.0%*
Severity: SEVERE
Onset: EARLY
Fever Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Low Calcium Levels Incidence:
<5.0%*
Severity: SEVERE
Onset: DELAYED
High Bilirubin Level Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Headache Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Constipation Incidence:
0.9-1.0%*
Severity: SEVERE
Onset: DELAYED
Elevated Hepatic Enzymes Incidence:
>0.9%*
Severity: SEVERE
Onset: DELAYED
Weight Loss Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Decreased Appetite Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Low Platelet Count Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Infection Incidence:
1.0-2.2%*
Severity: SEVERE
Onset: DELAYED
Anemia Incidence:
2.0-4.1%*
Severity: SEVERE
Onset: DELAYED
Nerve Pain Incidence:
3.1-8.0%*
Severity: SEVERE
Onset: DELAYED
Shortness Of Breath Incidence:
4.0%*
Severity: SEVERE
Onset: EARLY
Lightheadedness Incidence:
5.0-9.9%*
Severity: MILD
Onset: EARLY
Metallic Taste Incidence:
5.0-9.9%*
Severity: MILD
Onset: EARLY
Secretion Of Tears Incidence:
5.0-9.9%*
Severity: MILD
Onset: EARLY
Nervousness Incidence:
5.0-9.9%*
Severity: MILD
Onset: DELAYED
Muscle And/Or Bone Pain Incidence:
5.0-9.9%*
Severity: MILD
Onset: EARLY
Skin Rash Incidence:
5.0-9.9%*
Severity: MILD
Onset: EARLY
Weakness Incidence:
5.0-9.9%*
Severity: MILD
Onset: EARLY
Fluid Retention Incidence:
5.0-12.0%*
Severity: MODERATE
Onset: DELAYED
Muscle Cramps Incidence:
5.0-9.9%*
Severity: MILD
Onset: DELAYED
Increased Blood Sugar Incidence:
5.0-9.9%*
Severity: MODERATE
Onset: DELAYED
Depression Incidence:
5.0-9.9%*
Severity: MODERATE
Onset: DELAYED
Dry Skin Incidence:
5.0-9.9%*
Severity: MILD
Onset: DELAYED
Upset Stomach Incidence:
5.0-9.9%*
Severity: MILD
Onset: EARLY
Inability To Sleep Incidence:
5.0-9.9%*
Severity: MILD
Onset: EARLY
Low Blood Pressure Incidence:
5.0-9.9%*
Severity: MODERATE
Onset: RAPID
Cough Incidence:
14.0-18.0%*
Severity: MILD
Onset: DELAYED
Loose Stools Incidence:
17.0-18.0%*
Severity: MILD
Onset: EARLY
Low White Blood Cells Incidence:
32.0-57.0%*
Severity: SEVERE
Onset: DELAYED
Hair Loss Incidence:
35.0-45.0%*
Severity: MILD
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

SECOND Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

THIRD Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Halaven

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5